Achmea Investment Management B.V. Buys 8,428 Shares of Abbott Laboratories $ABT

Achmea Investment Management B.V. boosted its position in shares of Abbott Laboratories (NYSE:ABT) by 5.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 151,770 shares of the healthcare product maker’s stock after buying an additional 8,428 shares during the quarter. Achmea Investment Management B.V.’s holdings in Abbott Laboratories were worth $20,328,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Oarsman Capital Inc. boosted its holdings in Abbott Laboratories by 2.4% during the 3rd quarter. Oarsman Capital Inc. now owns 5,738 shares of the healthcare product maker’s stock valued at $769,000 after acquiring an additional 136 shares during the period. Centaurus Financial Inc. increased its stake in Abbott Laboratories by 2.8% in the third quarter. Centaurus Financial Inc. now owns 3,964 shares of the healthcare product maker’s stock worth $531,000 after purchasing an additional 109 shares during the period. First Affirmative Financial Network lifted its position in shares of Abbott Laboratories by 18.0% during the third quarter. First Affirmative Financial Network now owns 5,157 shares of the healthcare product maker’s stock worth $691,000 after purchasing an additional 788 shares during the last quarter. Mayport LLC lifted its position in shares of Abbott Laboratories by 4.6% during the third quarter. Mayport LLC now owns 3,826 shares of the healthcare product maker’s stock worth $512,000 after purchasing an additional 170 shares during the last quarter. Finally, First Commonwealth Financial Corp PA boosted its stake in shares of Abbott Laboratories by 7.1% during the third quarter. First Commonwealth Financial Corp PA now owns 13,649 shares of the healthcare product maker’s stock valued at $1,828,000 after purchasing an additional 908 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares in the company, valued at $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock worth $353,097 in the last three months. 0.46% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. BTIG Research dropped their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Argus reduced their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Finally, Sanford C. Bernstein dropped their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Price Performance

ABT opened at $110.80 on Wednesday. The firm has a market cap of $192.98 billion, a price-to-earnings ratio of 29.79, a PEG ratio of 1.75 and a beta of 0.74. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $139.06. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The stock’s 50-day moving average price is $113.91 and its 200 day moving average price is $123.50.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the prior year, the business earned $1.34 EPS. Abbott Laboratories’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.